Matrix metalloproteinase-2 and-9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity

被引:14
作者
Ertugrul, Goksen [1 ,3 ]
Keles, Didem [2 ]
Oktay, Gulgun [2 ]
Aktan, Sebnem [1 ]
机构
[1] Dokuz Eylul Univ, Sch Med, Dept Dermatol & Venereol, TR-35340 Izmir, Turkey
[2] Dokuz Eylul Univ, Sch Med, Dept Med Biochem, TR-35340 Izmir, Turkey
[3] Karabuk Univ Training & Res Hosp, Dept Dermatol & Venereol, TR-78200 Karabuk, Turkey
关键词
Matrix metalloproteinase-2; Matrix metalloproteinase-9; Tissue inhibitors of metalloproteinase-1; Gelatin zymography; Cutaneous lupus erythematosus; MATRIX-METALLOPROTEINASE-9; CELLS; MMP-9; EXPRESSION;
D O I
10.1007/s00403-018-1811-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Lupus erythematosus is a chronic autoimmune disease characterized by remissions and exacerbations. Accumulated evidence indicated that matrix metalloproteinases (MMPs) are upregulated in inflammatory cells of cutaneous lupus erythematosus (CLE); however, the activity levels of these proteases have remained uncharacterized. To elucidate the significance of MMP-2, MMP-9, and TIMP-1 in CLE pathogenesis, gelatin zymography was used to investigate pro and active levels of MMP-2 and MMP-9 in lesional and perilesional skin biopsies obtained from twenty-two CLE patients. TIMP-1 protein levels were detected by ELISA in the biopsy specimens. The correlation between biochemical parameters and clinical characteristics of the disease was also evaluated. Significantly higher levels of active MMP-2, active MMP-9, proMMP-9, active/proMMP-2, and TIMP-1 were detected in lesional skin samples. Besides, the active/proMMP-9 was elevated in female and smoking patients. Active MMP-9 levels and active/proMMP-9 were also increased in elderly patients. Active MMP-9 levels were lower in patients who had smaller total damage score. Consistently, active/proMMP-9 and active/proMMP-2 were positively correlated with CLASI. Interestingly, in hydroxychloroquine or topical corticosteroid-treated patients, MMP-2/-9 activity levels were found to be higher compared to untreated patients. These findings suggest that increased MMP-2 and MMP-9 activities may contribute to the pathogenesis of CLE and cutaneous disease severity.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 27 条
[1]   Sex hormones and the genesis of autoimmunity [J].
Ackerman, LS .
ARCHIVES OF DERMATOLOGY, 2006, 142 (03) :371-376
[2]   Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus [J].
Albrecht, Joerg ;
Werth, Victoria P. .
DERMATOLOGIC THERAPY, 2007, 20 (02) :93-101
[3]   Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques [J].
Axisa, B ;
Loftus, IM ;
Naylor, AR ;
Goodall, S ;
Jones, L ;
Bell, PRF ;
Thompson, MM .
STROKE, 2002, 33 (12) :2858-2864
[4]   Matrix metalloprotease inhibitors: design from structure [J].
Borkakoti, N .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :17-20
[5]   Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus [J].
Chang, Yih-Hsin ;
Lin, I-Ling ;
Tsay, Gregory J. ;
Yang, Shun-Chun ;
Yang, Tzi-Peng ;
Ho, Kuo-Ting ;
Hsu, Tsai-Ching ;
Shiau, Ming-Yuh .
CLINICAL BIOCHEMISTRY, 2008, 41 (12) :955-959
[6]  
Djamgoz MBA, 2001, J CELL SCI, V114, P2697
[7]   A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus [J].
Faber-Elmann, A ;
Eilat, E ;
Zinger, H ;
Mozes, E .
CLINICAL IMMUNOLOGY, 2002, 105 (02) :223-232
[8]   Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus [J].
Faber-Elmann, A ;
Sthoeger, Z ;
Tcherniack, A ;
Dayan, M ;
Mozes, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 127 (02) :393-398
[9]   Cutaneous MMPs are differently modulated by environmental stressors in old and young mice [J].
Fortino, Vittoria ;
Maioli, Ernanuela ;
Torricelli, Claudia ;
Davis, Paul ;
Valacchi, Giuseppe .
TOXICOLOGY LETTERS, 2007, 173 (02) :73-79
[10]   Impaired clearance of dying cells in systemic lupus erythematosus [J].
Gaipl, US ;
Voll, RE ;
Sheriff, A ;
Franz, S ;
Kalden, JR ;
Herrmann, M .
AUTOIMMUNITY REVIEWS, 2005, 4 (04) :189-194